Compare SRG & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRG | EQ |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.5M | 129.0M |
| IPO Year | N/A | 2018 |
| Metric | SRG | EQ |
|---|---|---|
| Price | $2.52 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 250.2K | ★ 300.0K |
| Earning Date | 05-14-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.39 | $0.29 |
| 52 Week High | $4.56 | $2.70 |
| Indicator | SRG | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 41.99 |
| Support Level | $2.43 | $1.60 |
| Resistance Level | $2.80 | $2.13 |
| Average True Range (ATR) | 0.10 | 0.22 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 43.28 | 7.10 |
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.